Bristol-Myers Squibb Co, the maker of Excedrin painkillers, said it received a subpoena from the US Attorney in Boston over pricing and marketing of drugs covered by Medicare and Medicaid.
Last month, New York-based Bristol-Myers said it started an internal review of its sales and marketing practices to make sure they don't violate laws.
The drugmaker shared information about its probe with representatives of the US attorney, who then subpoenaed the company, according to a regulatory filing.
The internal review focuses on whether Bristol-Myers's practices comply with anti-kickback laws and pricing requirements under the Medicaid program, the drugmaker said in its filing with the US Securities and Exchange Commission.
Medicaid, which is funded by the US and states, is the government health-insurance program for the poor. Medicare is the US health-insurance program for the elderly and disabled.
Government prosecutors have been cracking down on drugmakers who failed to give the best price for a medicine to government health-insurance programs or whose marketing practices resulted in fraudulent reimbursement claims.
Bristol-Myers and other drug companies have received requests for documents from the Office of the Inspector General of the Department of Health and Human Services and several states as well as the US attorney in Boston.
The filing didn't say when the subpoena was received. The investigations could result in criminal or civil claims, according to the filing.
Shares of Bristol-Myers fell US$0.07 to US$26.02 as of 4:15pm in New York Stock Exchange composite trading.
Samantha Martin, a spokeswoman for the US attorney in Massachusetts, didn't return a call made Friday evening.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained